Digital health service Forth approaches 50pc of Crowdcube target

Hoping to raise £150,000 on Crowdcube, Forth is a digital health service that tracks what’s happening to your body on the inside. The fitness startup offers consumers the ability to test and track over 50 internal biomarkers integral to performance, health and wellbeing.

Approaching the 50 percent marker of its total goal, the Bristol-based startup is hoping to grab a slice a slice of the fitness app industry, where one in three of the world’s online population are using technology to track their health and fitness.

“Forth goes beyond surface level markers giving people direct access to accredited laboratory testing. Our service is fast and convenient, and most of our test samples can be collected at home using a finger prick kit. Analysed results are converted by our software into intuitive graphics which can be tracked over time through a personal health dashboard.”

CEO, Sarah Bolt, has worked exclusively within the healthcare sector for the past eight years and is confident in the platform’s potential.

Sarah Bolt, CEO.

“Forth helps people to be healthier, fitter and stronger by tracking what’s happening to their body on the inside,” Sarah explains, in an interview with TechSpark. “By profiling your biomarkers you can understand your body like never before, which helps you to make the right choices to protect your ongoing health and improve performance.”

Their business model is based on retailing laboratory testing direct to consumers. There is also potential to expand the business into other areas including, nutritional and training plans, online consultations and supplements.

“Our sales strategy is focused on two key channels: driving sales through affiliates and stimulating sales direct with consumers. We aim to form 100 affiliate partnerships by the end of 2017, delivering almost 50% of our sales forecast. We anticipate that the remaining sales will be generated directly from consumers.”

Sarah is planning an exit strategy in five years, where the possible routes include pharmaceutical companies who value data or private healthcare providers such as Spire (LON:SPI) and Nuffield Health.

More articles ―